Bristol-Myers Squibb Co. (BMY): Price and Financial Metrics

BMY POWR Grades

• BMY scores best on the Value dimension, with a Value rank ahead of 97.2% of US stocks.
• The strongest trend for BMY is in Stability, which has been heading up over the past 52 weeks.
• BMY's current lowest rank is in the Momentum metric (where it is better than 4.46% of US stocks).

BMY Stock Summary

• With a market capitalization of $127,971,519,517, Bristol Myers Squibb Co has a greater market value than 98.04% of US stocks.
• Bristol Myers Squibb Co's stock had its IPO on January 1, 1986, making it an older stock than 92.73% of US equities in our set.
• The volatility of Bristol Myers Squibb Co's share price is greater than that of just 6.28% US stocks with at least 200 days of trading history.
• Stocks with similar financial metrics, market capitalization, and price volatility to Bristol Myers Squibb Co are AMGN, BP, DE, COP, and RIO.
• Visit BMY's SEC page to see the company's official filings. To visit the company's web site, go to www.bms.com.

BMY Valuation Summary

• BMY's EV/EBIT ratio is -44.2; this is 250.85% lower than that of the median Healthcare stock.
• Over the past 243 months, BMY's price/sales ratio has gone down 2.6.
• BMY's price/sales ratio has moved down 2.6 over the prior 243 months.

Below are key valuation metrics over time for BMY.

BMY Growth Metrics

• Its year over year revenue growth rate is now at 38.07%.
• Its 2 year cash and equivalents growth rate is now at 196.09%.
• The 5 year price growth rate now stands at 1.4%.

Over the past 30 months, BMY's revenue has gone up $21,823,000,000.

The table below shows BMY's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-06-30	44,384	12,773	-5,079
2021-03-31	42,810	13,982	-6,219
2020-12-31	42,518	14,052	-9,015
2020-09-30	39,395	12,420	-44
2020-06-30	34,862	12,757	-563
2020-03-31	31,006	10,571	954

BMY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• BMY has a Quality Grade of B, ranking ahead of 81.66% of graded US stocks.
• BMY's asset turnover comes in at 0.38 -- ranking 125th of 681 Pharmaceutical Products stocks.
• PAHC, ACUR, and XLRN are the stocks whose asset turnover ratios are most correlated with BMY.

The table below shows BMY's key quality metrics over time.